Ai-Media Technologies Ltd
- Country
- ๐บ๐ธUnited States
- Ownership
- -
- Employees
- 610
- Market Cap
- $20.9M
- Introduction
AIM ImmunoTech, Inc. is a immuno-pharma company, which focuses on the research and development of therapeutics to treat multiple types of cancers, various viruses and immune-deficiency disorders. Its products include Alferon N Injection and Ampligen. The Alferon N Injection is a purified, natural source, glycosylated, multispecies alpha interferon product, composed of eight forms of high-purified alpha interferon. The Ampligen is used in the treatment of chronic fatigue syndrome and as a vaccine enhancer for therapeutic and/or preventative development related to influenza and cancer treatments. The company was founded in August 1966 and is headquartered in Ocala, FL.
Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
- Conditions
- Long COVIDPost COVID-19 Condition
- Interventions
- Other: Placebo / Normal SalineDrug: Rintatolimod
- First Posted Date
- 2022-10-24
- Last Posted Date
- 2024-01-22
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT05592418
- Locations
- ๐บ๐ธ
Acclaim Clinical Research, San Diego, California, United States
๐บ๐ธZenos Clinical Research, Dallas, Texas, United States
๐บ๐ธAlfa Medical Research, Davie, Florida, United States
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
- First Posted Date
- 2022-08-10
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 90
- Registration Number
- NCT05494697
- Locations
- ๐บ๐ธ
Virginia Mason Medical Center, Seattle, Washington, United States
๐บ๐ธNebraska Medical Center, Omaha, Nebraska, United States
๐บ๐ธGabrail Cancer Center Research, Canton, Ohio, United States
Safety Study of FluMist With and Without Ampligen
- Conditions
- Influenza, Human
- Interventions
- Drug: FluMistDrug: Placebo
- First Posted Date
- 2012-05-04
- Last Posted Date
- 2018-07-26
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 55
- Registration Number
- NCT01591473
- Locations
- ๐บ๐ธ
The University of Alabama at Birmingham, Birmingham, Alabama, United States
Study of Alferonยฎ LDO (Low Dose Oral) in Normal Volunteers
- Conditions
- Severe Acute Respiratory Syndrome
- Interventions
- Drug: Alferon LDO
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT00215826
- Locations
- ๐ญ๐ฐ
Princess Margaret Hospital, Lai Chi Kok, Kowloon, Hong Kong
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
- Conditions
- Chronic Fatigue SyndromeMyalgic Encephalomyelitis
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT00215800
A Randomized, Dose-ranging Study of Alferon LDO in Asymptomatic HIV+ Subjects
- Conditions
- HIV Infections
- Interventions
- Drug: Alferon LDO
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-09-04
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 17
- Registration Number
- NCT00215852
- Locations
- ๐บ๐ธ
Drexel University School of Medicine, Philadelphia, Pennsylvania, United States
๐บ๐ธPhiladelphia FIGHTS, Philadelphia, Pennsylvania, United States
Ampligen in Chronic Fatigue Syndrome
- Conditions
- Chronic Fatigue Syndrome
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2024-04-12
- Lead Sponsor
- AIM ImmunoTech Inc.
- Registration Number
- NCT00215813
- Locations
- ๐บ๐ธ
Sierra Internal Medicine, Incline Village, Nevada, United States
๐บ๐ธHunter-Hopkins Center, PA, Charlotte, North Carolina, United States
The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART
- Conditions
- HIV SeropositivityHIV Infection
- Interventions
- Drug: poly I-poly C12U
- First Posted Date
- 2002-05-07
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00035893
- Locations
- ๐บ๐ธ
AltaMed Health Services Corporation, Los Angeles, California, United States
๐บ๐ธSt. Michael's Medical Center, Newark, New Jersey, United States
๐บ๐ธAllied Clinical Trials, Miami, Florida, United States
Safety and Efficacy of Ampligen in the Treatment of HIV Patients Failing HAART
- Conditions
- HIV SeropositivityHIV Infection
- Interventions
- Drug: poly I-poly C12U
- First Posted Date
- 2002-05-06
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT00035581
- Locations
- ๐บ๐ธ
Orange County Center for Special Immunology, Fountain Valley, California, United States
๐บ๐ธJulia Torres, MD, Fort Lauderdale, Florida, United States
๐บ๐ธSt. Michael's Medical Center, Newark, New Jersey, United States